The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue of cancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market. Monoclonal antibodies are very specific in nature and have limited targets.A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cancer-monoclonal-antibodies-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Cancer monoclonal antibodies market has been segmented based on application, type and conjugation, and distribution channel
Base on application, cancer monoclonal antibodies market is segmented into
Breast Cancer
Blood Cancer
Liver Cancer
Brain cancer
Colorectal Cancer
Others
Based on type of antibody, cancer monoclonal antibodies market is segmented into
Murine Antibodies
Humanized Antibodies
Chimeric Antibodies
Based on conjugation, cancer monoclonal antibodies market is segmented into
Immunocytokines
Immunoliposome
Radioimmunotherapy
Antibody Directed Enzyme Prodrug Therapy(ADEPT)
Based on distribution channel, cancer monoclonal antibodies market segmented into
Hospital Pharmacies
Retail Pharmacies
Clinics
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cancer-monoclonal-antibodies-market/#ulp-c654SbFYO64MsOhu[/URL]
Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets.
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-cancer-monoclonal-antibodies-market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in cancer monoclonal antibodies market are Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi (France) and AstraZeneca (U.K.) to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"